vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Identiv, Inc. (INVE). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $6.2M, roughly 1.7× Identiv, Inc.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -60.3%, a 83.8% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -7.9%). Over the past eight quarters, Identiv, Inc.'s revenue compounded faster (-3.8% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Identiv is a publicly traded Internet of Things technology company listed on the Nasdaq stock market.
ABUS vs INVE — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $6.2M |
| Net Profit | $2.5M | $-3.7M |
| Gross Margin | — | 18.1% |
| Operating Margin | 13.9% | -76.4% |
| Net Margin | 23.5% | -60.3% |
| Revenue YoY | 522.2% | -7.9% |
| Net Profit YoY | 112.7% | -948.2% |
| EPS (diluted) | $0.01 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $6.2M | ||
| Q3 25 | — | $5.0M | ||
| Q2 25 | $10.7M | $5.0M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | — | $6.5M | ||
| Q2 24 | — | $6.7M | ||
| Q1 24 | — | $6.7M |
| Q4 25 | — | $-3.7M | ||
| Q3 25 | — | $-3.5M | ||
| Q2 25 | $2.5M | $-6.0M | ||
| Q1 25 | — | $-4.8M | ||
| Q4 24 | — | $-355.0K | ||
| Q3 24 | — | $85.9M | ||
| Q2 24 | — | $-6.2M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | 18.1% | ||
| Q3 25 | — | 10.7% | ||
| Q2 25 | — | -9.4% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | -14.9% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | 9.1% | ||
| Q1 24 | — | 7.3% |
| Q4 25 | — | -76.4% | ||
| Q3 25 | — | -111.4% | ||
| Q2 25 | 13.9% | -126.7% | ||
| Q1 25 | — | -103.8% | ||
| Q4 24 | — | -98.9% | ||
| Q3 24 | — | -146.2% | ||
| Q2 24 | — | -99.7% | ||
| Q1 24 | — | -76.0% |
| Q4 25 | — | -60.3% | ||
| Q3 25 | — | -68.9% | ||
| Q2 25 | 23.5% | -119.9% | ||
| Q1 25 | — | -90.9% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | 1315.8% | ||
| Q2 24 | — | -92.2% | ||
| Q1 24 | — | -68.5% |
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.15 | ||
| Q2 25 | $0.01 | $-0.26 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | — | $3.62 | ||
| Q2 24 | — | $-0.27 | ||
| Q1 24 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $128.6M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $140.7M |
| Total Assets | $103.3M | $151.3M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $128.6M | ||
| Q3 25 | — | $126.3M | ||
| Q2 25 | $37.4M | $129.3M | ||
| Q1 25 | — | $132.4M | ||
| Q4 24 | — | $135.6M | ||
| Q3 24 | — | $145.4M | ||
| Q2 24 | — | $18.4M | ||
| Q1 24 | — | $21.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $140.7M | ||
| Q3 25 | — | $143.7M | ||
| Q2 25 | $83.0M | $146.4M | ||
| Q1 25 | — | $150.5M | ||
| Q4 24 | — | $154.1M | ||
| Q3 24 | — | $156.7M | ||
| Q2 24 | — | $65.1M | ||
| Q1 24 | — | $70.2M |
| Q4 25 | — | $151.3M | ||
| Q3 25 | — | $151.0M | ||
| Q2 25 | $103.3M | $153.9M | ||
| Q1 25 | — | $158.7M | ||
| Q4 24 | — | $163.2M | ||
| Q3 24 | — | $177.0M | ||
| Q2 24 | — | $97.8M | ||
| Q1 24 | — | $101.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $3.0M |
| Free Cash FlowOCF − Capex | — | $2.8M |
| FCF MarginFCF / Revenue | — | 45.8% |
| Capex IntensityCapex / Revenue | 0.0% | 3.3% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-7.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.0M | ||
| Q3 25 | — | $-2.9M | ||
| Q2 25 | $-15.7M | $-3.6M | ||
| Q1 25 | — | $-3.3M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | — | $-7.2M | ||
| Q2 24 | — | $-993.0K | ||
| Q1 24 | — | $-1.3M |
| Q4 25 | — | $2.8M | ||
| Q3 25 | — | $-3.2M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | — | $-6.5M | ||
| Q3 24 | — | $-7.7M | ||
| Q2 24 | — | $-1.1M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | 45.8% | ||
| Q3 25 | — | -64.5% | ||
| Q2 25 | — | -75.8% | ||
| Q1 25 | — | -68.0% | ||
| Q4 24 | — | -97.7% | ||
| Q3 24 | — | -118.2% | ||
| Q2 24 | — | -16.7% | ||
| Q1 24 | — | -23.0% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | — | 5.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.08× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
INVE
| Other | $3.4M | 55% |
| Europe And Middle East | $2.2M | 36% |
| Asia Pacific | $575.0K | 9% |
